RDNT Stock Analysis
RD
Avoid
Based on Eyestock quantitative analysis, RDNT`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. The company is headquartered in Los Angeles, California and currently employs 6,946 full-time employees. The company went IPO on 2001-12-12. The firm operates directly or indirectly through joint ventures with hospitals, 357 centers located in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company operates through two segments: Imaging Center and Artificial Intelligence (AI). The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The company also provides teleradiology services in the United Kingdom. The AI segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.